86 related articles for article (PubMed ID: 1913666)
1. Pharmacokinetics of pyrazoloacridine in the rhesus monkey.
Berg SL; Balis FM; McCully CL; Godwin KS; Poplack DG
Cancer Res; 1991 Oct; 51(20):5467-70. PubMed ID: 1913666
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L
Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.
Foster BJ; Wiegand RA; LoRusso PM; Baker LH
Clin Cancer Res; 1995 Aug; 1(8):831-7. PubMed ID: 9816052
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
5. A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients.
Grem JL; Harold N; Keith B; Chen AP; Kao V; Takimoto CH; Hamilton JM; Pang J; Pace M; Jasser GB; Quinn MG; Monahan BP
Clin Cancer Res; 2002 Jul; 8(7):2149-56. PubMed ID: 12114415
[TBL] [Abstract][Full Text] [Related]
6. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates.
Blaney SM; Cole DE; Balis FM; Godwin K; Poplack DG
Cancer Res; 1993 Feb; 53(4):725-7. PubMed ID: 8428353
[TBL] [Abstract][Full Text] [Related]
7. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocyte-colony stimulating factor.
Berg SL; Savarese DM; Balis FM; Denicoff AM; Hillig M; O'Shaughnessy JA; Poplack DG; Cowan KH
Cancer Res; 1993 Jun; 53(11):2587-90. PubMed ID: 7684320
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
10. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
[TBL] [Abstract][Full Text] [Related]
11. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme.
Graham MA; Newell DR; Foster BJ; Gumbrell LA; Jenns KE; Calvert AH
Cancer Res; 1992 Feb; 52(3):603-9. PubMed ID: 1732048
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of tiazofurin in the plasma and cerebrospinal fluid of rhesus monkeys.
Grygiel JJ; Balis FM; Collins JM; Lester CM; Poplack DG
Cancer Res; 1985 May; 45(5):2037-9. PubMed ID: 3986760
[TBL] [Abstract][Full Text] [Related]
14. Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial.
Kestell P; Dunlop IC; McCrystal MR; Evans BD; Paxton JW; Gamage RS; Baguley BC
Cancer Chemother Pharmacol; 1999; 44(1):45-50. PubMed ID: 10367748
[TBL] [Abstract][Full Text] [Related]
15. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial and pharmacokinetic evaluation of fazarabine in children.
Heideman RL; Gillespie A; Ford H; Reaman GH; Balis FM; Tan C; Sato J; Ettinger LJ; Packer RJ; Poplack DG
Cancer Res; 1989 Sep; 49(18):5213-6. PubMed ID: 2475244
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
19. Phase I and clinical pharmacology trial of 502U83 using a monthly single dose schedule.
Von Hoff DD; Kuhn JG; Havlin KA; Langevin AM; Brown TD; Weiss GR; Turner JN; Purvis J; Lucas VS; Bair KW
Cancer Res; 1990 Dec; 50(23):7496-500. PubMed ID: 2253197
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
